The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Peri-operative modified FOLFIRINOX in resectable pancreatic cancer: A pilot study.
 
Robert de Wilton Marsh
No Relationships to Disclose
 
Shuang Qin Zhang
Consulting or Advisory Role - Boehringer Ingelheim
 
Marshall Baker
No Relationships to Disclose
 
Daniel V.T. Catenacci
Honoraria - Amgen; Foundation Medicine; Genentech/Roche; Genmab; Lilly; OncoPlex Diagnostics; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Genentech/Roche; OncoPlex Diagnostics
Speakers' Bureau - Foundation Medicine; Lilly; OncoPlex Diagnostics
Research Funding - Amgen; Genentech; OncoPlex Diagnostics
 
Mark Kozloff
Honoraria - Abbvie; Celgene; Genentech; Lilly; Roche/Genentech
Consulting or Advisory Role - Abbvie; Roche/Genentech
Speakers' Bureau - Celgene; Lilly; Roche/Genentech
 
Blase N. Polite
Speakers' Bureau - Bayer/Onyx
Research Funding - Merck
Other Relationship - Gerson Lehrman Group
 
Mitchell C. Posner
Consulting or Advisory Role - Sirtex Medical
 
Kevin K. Roggin
No Relationships to Disclose
 
Mark S. Talamonti
No Relationships to Disclose
 
Kristen Wroblewski
No Relationships to Disclose
 
Hedy L. Kindler
Consulting or Advisory Role - Aduro Biotech; AstraZeneca; Bayer; Celgene; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; MedImmune; Merck; Plexxikon; Verastem
Research Funding - AB Science; Aduro Biotech; Astellas Pharma; AstraZeneca; Bayer; Celgene; GlaxoSmithKline; Incyte; MedImmune; Merck; Verastem